VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PRTA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PRTAProthena Corporation plc
$7.89$413M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksPRTABalance Sheet

Prothena Corporation plc (PRTA) Balance Sheet

16Y historyFree accessUpdated daily

The balance sheet is conservatively leveraged with a debt-to-equity ratio of 0.02, but the asset base has shrunk by 44% from $623.2M in 2024Q1 to $302.6M in 2026Q2 due to sustained cash consumption.

Income StatementBalance SheetCash FlowRatios

PRTA Balance Sheet

Annual statement

PRTA Balance Sheet

Prothena Corporation plc (PRTA) balance sheet — 16-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Total Current Assets292.01M315.19M485.41M639.28M719.1M584.81M299.28M378.38M431.39M426.33M391.36M377.4M299.27M178.22M125.84M124K0
Cash & Short-Term Investments288.19M307.53M471.39M618.83M710.41M579.09M295.38M375.72M427.66M417.62M386.92M370.59M293.58M176.68M124.86M00
Cash Only288.19M307.53M471.39M618.83M710.41M579.09M295.38M375.72M427.66M417.62M386.92M370.59M293.58M176.68M124.86M00
Short-Term Investments00000000000000000
Accounts Receivable0005.16M62K13K15K68K2K240K178K509K1.76M58K223K00
Days Sales Outstanding---20.610.420.026.4230.490.763.1861.58115.6112.6331.3230.62--
Inventory000000000-240K-178K-509K-1.76M-58K-223K00
Days Inventory Outstanding-----------------
Other Current Assets3.82M1.75M1.17M3.49M1.71M766K1.35M00000081K73K00
Total Non-Current Assets10.57M11.61M61.7M57.1M38.94M24.56M33.69M40.89M67.41M70M68.61M7.83M4.84M4.19M3.44M3.49M3.3M
Property, Plant & Equipment9.22M10.27M13.79M16M8.01M14.13M20.36M27.15M52.84M54.99M56.45M3.86M3.12M3.37M3.39M2.54M2.4M
Fixed Asset Turnover5.43x0.94x9.80x5.71x6.73x14.19x0.04x0.03x0.02x0.50x0.02x0.42x16.29x0.20x0.78x0.20x0.52x
Goodwill00000000000000000
Intangible Assets0000000000000049K70K0
Long-Term Investments3.44M860K860K000004.06M4.06M4.06M000-122K00
Other Non-Current Assets482K482K3.81M7.21M12.72M3.35M1.69M3.79M4.87M6.9M6.25M1.12M0049K885K900K
Total Assets302.58M326.8M547.11M696.38M758.03M609.37M332.98M419.27M498.8M496.33M459.98M385.24M304.12M182.41M129.28M3.62M3.3M
Asset Turnover0.16x0.03x0.25x0.13x0.07x0.33x0.00x0.00x0.00x0.06x0.00x0.00x0.17x0.00x0.02x0.14x0.38x
Asset Growth %-134.57%-40.27%-21.44%-8.13%24.4%83.01%-20.58%-15.94%0.5%7.9%19.4%26.67%66.72%41.09%3473.33%9.64%-
Total Current Liabilities11.66M40.84M48.5M56.89M50.15M33.45M25.85M17.71M14.93M37.37M41.08M22.22M12.04M7.41M1.74M8.4M1.8M
Accounts Payable1.94M5.88M7.77M25.39M9.27M3.69M4.12M1.24M1.47M13.63M13.07M4.52M4.72M1.79M0380K100K
Days Payables Outstanding67.01579.25----20.078.925.336.9839.9128.2244.8225.08---
Short-Term Debt2.96M2.89M000000000000000
Deferred Revenue (Current)7.6M2.66M8.85M011.44M7.66M00110.24M-857K363K284K00000
Other Current Liabilities6.14M29.42M1.38M2.13M503K405K516K322K837K1.72M1.87M804K725K658K51K288K1.2M
Current Ratio25.05x7.72x10.01x11.24x14.34x17.48x11.58x21.36x28.90x11.41x9.53x16.99x24.86x24.06x72.16x0.01x-
Quick Ratio25.05x7.72x10.01x11.24x14.34x17.48x11.58x21.36x28.90x11.41x9.53x17.01x25.00x24.07x72.28x0.01x-
Cash Conversion Cycle-----------------
Total Non-Current Liabilities4.03M5.49M11.68M78.13M85.85M109.87M123.12M128.63M160.87M51.77M53.5M2.35M2.19M1.73M1.05M1.65M1.4M
Long-Term Debt05.49M000000000000000
Capital Lease Obligations15.72M5.49M8.23M10.72M06.39M12.33M17.84M49.9M51.52M51.32M000000
Deferred Tax Liabilities00000000-49.9M-254K-2.08M01.72M0000
Other Non-Current Liabilities0-5.49M00553K553K553K553K110.97M254K2.18M2.35M468K1.73M1.05M1.65M0
Total Liabilities15.69M46.33M60.18M135.02M135.99M143.32M148.97M146.35M175.8M89.14M94.57M24.57M14.23M9.14M2.8M10.05M3.2M
Total Debt6.99M13.86M10.84M11.84M6.47M12.33M17.84M22.94M51.55M52.25M51.32M000000
Net Debt-281.2M-293.67M-460.55M-607M-703.93M-566.77M-277.54M-352.78M-376.11M-365.37M-335.6M-370.59M-293.58M-176.68M-124.86M00
Debt / Equity0.02x0.05x0.02x0.02x0.01x0.03x0.10x0.08x0.16x0.13x0.14x------
Debt / EBITDA-0.12x----0.17x-----------
Net Debt / EBITDA4.66x-----7.75x-----------
Interest Coverage---------41.23x-41.73x-184.20x------
Total Equity286.89M280.47M486.93M561.37M622.04M466.04M184.01M272.92M323M407.19M365.4M360.67M289.89M173.27M126.48M-6.44M100K
Equity Growth %-127.31%-42.4%-13.26%-9.75%33.47%153.28%-32.58%-15.5%-20.68%11.44%1.31%24.42%67.3%36.99%2065.26%-6536%-
Book Value per Share5.505.219.0610.5513.139.624.616.848.1610.8110.6411.8911.759.318.67-0.360.01
Total Shareholders' Equity286.89M280.47M486.93M561.37M622.04M466.04M184.01M272.92M323M407.19M365.4M360.67M289.89M173.27M126.48M-6.44M100K
Common Stock517K538K538K537K521K466K399K399K399K385K348K317K274K219K177K00
Retained Earnings-1.33B-1.35B-1.1B-980.03M-833M-716.05M-783.03M-671.88M-598M-442.35M-289.21M-129.1M-48.49M-41.34M-345K0-12.5M
Treasury Stock00000000000000000
Accumulated OCI00000000-10.5M-7.74M-7.67M-5.34M-4.71M-4.29M-3.71M-568K12.6M
Minority Interest00000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Sustained cash burn without profitability

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Asset Base Shrinking from Cash Burn

Total assets have declined by 44% from $623.2M in 2024Q1 to $302.6M in 2026Q2, a trend driven by the consistent consumption of cash reserves to fund operations and share repurchases, as reported in the company's financial statements.

The balance sheet trajectory is one of steady contraction, with the asset base shrinking each quarter as cash is deployed to cover operating losses and buybacks. This pattern suggests the company is in a phase of capital consumption, relying on its existing cash pile rather than generating new capital from operations. The shrinking asset base, absent a corresponding reduction in liabilities, indicates a business model that is currently eroding its financial cushion.

Cash Cushion Eroding but Still Substantial

Despite a 48% reduction in cash from $546.5M in 2024Q1 to $288.2M in 2026Q2, Prothena maintains an exceptionally high current ratio of 25.05, suggesting a significant, though diminishing, buffer against near-term liquidity shocks.

The company's liquidity position remains strong on a static basis, with cash representing over 95% of total assets. However, the trajectory is concerning, as the cash balance has been drawn down by approximately $258M over ten quarters to fund persistent operating losses and share repurchases. The current ratio, while extremely high, is a function of minimal current liabilities, and its sustainability depends entirely on the pace of future cash consumption.

Equity Eroded by Persistent Accumulated Deficit

Shareholders' equity has decreased from $502.4M to $286.9M over the last ten quarters, driven by an accumulated deficit that has deepened to -$1.3B, a figure that underscores the company's history of unprofitable operations.

The equity base is being steadily eroded by net losses, which have accumulated into a massive deficit. This structural weakness is partially offset by the company's large cash position, but the trend indicates that without a path to profitability, equity will continue to decline. The negative retained earnings balance is a clear signal that the business has historically consumed more capital than it has generated.

Cash Burn vs. Shareholder Returns Conflict

The company spent $15.6M on share repurchases in 2026Q2 alone while reporting a net loss of $18.6M, a capital allocation choice that appears misaligned with its status as a cash-burning, pre-profit biotech firm.

The most significant balance sheet distortion is the apparent conflict between the company's operational cash burn and its use of capital for share repurchases. This strategy may be intended to offset dilution from stock-based compensation, but it accelerates the depletion of the cash runway without contributing to operational growth. Investors should monitor whether this capital allocation continues as the cash balance declines, as it could force a future financing event.

PRTA — Frequently Asked Questions

Quick answers to the most common questions about buying PRTA stock.

What are the total assets of Prothena Corporation plc (PRTA)?

As of 2025, Prothena Corporation plc (PRTA) had total assets of $326.8M including $315.2M in current assets.

How much debt does Prothena Corporation plc (PRTA) have?

Prothena Corporation plc (PRTA) carries total debt of $13.9M, offset by $307.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Prothena Corporation plc?

Prothena Corporation plc (PRTA) has total shareholders' equity (book value) of $280.5M ($5.21 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Prothena Corporation plc's current ratio and liquidity?

Prothena Corporation plc (PRTA) reported a current ratio of 7.72x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.